2018
Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal Of Medicine 2018, 380: 539-548. PMID: 30415601, DOI: 10.1056/nejmoa1812851.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiac Output, LowDose-Response Relationship, DrugDouble-Blind MethodDrug CombinationsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainNeprilysinPeptide FragmentsStroke VolumeTetrazolesValsartanConceptsAcute decompensated heart failureDecompensated heart failureNT-proBNP concentrationsSacubitril-valsartan groupSacubitril-valsartan therapyReduced ejection fractionHeart failureSymptomatic hypotensionRenal functionEnalapril groupEjection fractionWeek 4N-terminal pro-B-type natriuretic peptide concentrationsAngiotensin-Neprilysin InhibitionKey safety outcomePrimary efficacy outcomeNatriuretic peptide concentrationsGreater reductionEnalapril therapyEfficacy outcomesHemodynamic stabilizationSafety outcomesBaseline valuesWeek 1PatientsRationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal 2018, 198: 145-151. PMID: 29653636, DOI: 10.1016/j.ahj.2018.01.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAminobutyratesBiphenyl CompoundsCardiac Output, LowCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsDrug Delivery SystemsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPatient SafetyPeptide FragmentsPrognosisProspective StudiesRisk AssessmentSeverity of Illness IndexSurvival RateTetrazolesTreatment OutcomeValsartanConceptsAcute decompensated heart failureSacubitril/valsartanB-type natriuretic peptideDecompensated heart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptideEjection fractionHeart failureHospital initiationNatriuretic peptideEnd pointClass angiotensin receptor neprilysin inhibitorAngiotensin receptor neprilysin inhibitorPg/Primary efficacy end pointAmbulatory HF patientsExploratory end pointsPIONEER-HF trialEfficacy end pointReduced ejection fractionSafety end pointOpen-label treatmentIncidence of angioedemaYears of agePIONEER-HF
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureComparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiuretics
2013
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. Circulation Heart Failure 2013, 6: 862-868. PMID: 23861505, PMCID: PMC3902033, DOI: 10.1161/circheartfailure.113.000394.Peer-Reviewed Original Research
2008
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Östergren J, Ibsen H, Weber M, Investigators F. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. Blood Pressure 2008, 17: 7-17. PMID: 18568687, DOI: 10.1080/08037050801972857.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAntihypertensive AgentsBenzazepinesBlood PressureDose-Response Relationship, DrugDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleFinlandHumansHydrochlorothiazideHypertensionMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsRacial GroupsRisk AssessmentScandinavian and Nordic CountriesTreatment OutcomeUnited StatesConceptsBlood pressureBP controlCombination therapyBaseline predictorsBP valuesCombination treatmentAbsolute BP valuesMain baseline predictorsPrevious antihypertensive medicationsLipid-lowering therapyUncontrolled blood pressureBlood pressure responseLarge outcome trialsLipid-lowering drugsSystolic BP valuesLogistic regression modelsBlinded baselineUncontrolled hypertensionAntihypertensive medicationsCardiovascular eventsSevere hypertensionSystolic hypertensionThiazide useOutcome trialsOverall patients
2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
Thomas KL, Al-Khatib SM, Lokhnygina Y, Solomon SD, Kober L, McMurray JJ, Califf RM, Velazquez EJ. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. American Heart Journal 2007, 155: 87-93. PMID: 18082495, DOI: 10.1016/j.ahj.2007.09.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmiodaroneCaptoprilCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProbabilityProportional Hazards ModelsReference ValuesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTetrazolesTreatment OutcomeValineValsartanVentricular DysfunctionConceptsVentricular systolic dysfunctionAmiodarone useAcute myocardial infarctionMyocardial infarctionSystolic dysfunctionLeft ventricular systolic dysfunctionPost-acute myocardial infarctionHazard ratio 1.5Higher Killip classTrials of amiodaroneKillip classVentricular dysfunctionBaseline characteristicsCardiovascular mortalityDiabetes mellitusHeart failureMedical regimenRandomized comparisonBaseline predictorsExcess mortalityCox modelSubsequent mortalityDay 1PatientsAmiodarone